These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32320302)

  • 1. The management of anti-infective agents in intensive care units: the potential role of a 'fast' pharmacology.
    Cattaneo D; Corona A; De Rosa FG; Gervasoni C; Kocic D; Marriott DJ
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):355-366. PubMed ID: 32320302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
    Sadilová K; Halačová M; Černý D
    Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis.
    Fujii M; Karumai T; Yamamoto R; Kobayashi E; Ogawa K; Tounai M; Lipman J; Hayashi Y
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):415-430. PubMed ID: 32238005
    [No Abstract]   [Full Text] [Related]  

  • 5. A survey on infection management practices in Italian ICUs.
    Bassetti M; De Gaudio R; Mazzei T; Morace G; Petrosillo N; Viale P; Bello G; La Face S; Antonelli M
    Crit Care; 2012 Nov; 16(6):R221. PubMed ID: 23151325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.
    Cattaneo D; Alffenaar JW; Neely M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.
    Roberts JA; De Waele JJ; Dimopoulos G; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J
    BMC Infect Dis; 2012 Jul; 12():152. PubMed ID: 22768873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antimicrobial agents for use in the intensive care unit.
    Ritchie DJ; Alexander BT; Finnegan PM
    Infect Dis Clin North Am; 2009 Sep; 23(3):665-81. PubMed ID: 19665089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials.
    Maraolo AE; Scotto R; Zappulo E; Pinchera B; Schiano Moriello N; Nappa S; Buonomo AR; Gentile I
    Expert Rev Anti Infect Ther; 2020 Mar; 18(3):191-202. PubMed ID: 32011191
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).
    Guilhaumou R; Benaboud S; Bennis Y; Dahyot-Fizelier C; Dailly E; Gandia P; Goutelle S; Lefeuvre S; Mongardon N; Roger C; Scala-Bertola J; Lemaitre F; Garnier M
    Crit Care; 2019 Mar; 23(1):104. PubMed ID: 30925922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
    Aubron C; Corallo CE; Nunn MO; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Oct; 45(10):1193-8. PubMed ID: 21896920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.
    Gatti M; Cojutti PG; Bartoletti M; Tonetti T; Bianchini A; Ramirez S; Pizzilli G; Ambretti S; Giannella M; Mancini R; Siniscalchi A; Viale P; Pea F
    Crit Care; 2022 Jun; 26(1):178. PubMed ID: 35701812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to treat severe infections in critically ill neutropenic patients?
    Zafrani L; Azoulay E
    BMC Infect Dis; 2014 Nov; 14():512. PubMed ID: 25431154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
    Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
    BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
    Tängdén T; Ramos Martín V; Felton TW; Nielsen EI; Marchand S; Brüggemann RJ; Bulitta JB; Bassetti M; Theuretzbacher U; Tsuji BT; Wareham DW; Friberg LE; De Waele JJ; Tam VH; Roberts JA;
    Intensive Care Med; 2017 Jul; 43(7):1021-1032. PubMed ID: 28409203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin: a review of its characteristics, activity, and use in intensive care units.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1213-1220. PubMed ID: 32662712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interscience Conference on Antimicrobial Agents and Chemotherapy--44th annual meeting. Drug highlights I. 30 October-2 November 2004, Washington DC, USA.
    Veryard C; Shah S
    IDrugs; 2004 Dec; 7(12):1058-61. PubMed ID: 15599792
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
    de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
    Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.